Texas Diabetes & Endocrinology

Austin, Texas 78749

4 studies enrolling now · 30 studies all time

What they study most

Cardiovascular Disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Early Alzheimer's Disease, Early Alzheimer´s Disease, Essential Hypertension, High Cardiovascular Risk, Hypogonadism, Non-Alcoholic Steatohepatitis, Obesity, Other Endocrine/Nutritional/Metabolic Disorder, Overweight

Studies at this site

• CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) — Recruiting now
• Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes — Recruiting now
• GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes — Recruiting now
• A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes — Recruiting now
• A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight — Running, not enrolling
• Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec — Completed
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) — Completed
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
• A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide — Starting soon
• A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before — Completed
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) — Completed
• A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes — Completed
• A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) — Completed
• Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home — Completed
• A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus — Stopped early
• Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics — Completed
• Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus — Completed
• A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH — Stopped early
• Investigational Study of Delayed Release Metformin — Paused
• Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension — Completed
• A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants — Completed
• Mylan Insulin Aspart Study — Completed
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis — Completed
• FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump — Completed
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Nutritional Supplement Impact on Metabolic Parameters — Completed
• Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention) — Completed
• A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port — Completed